- Home
- MRNA vs KOF Comparison
MRNA vs KOF Comparison
Compare MRNA & KOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- KOF
- Stock Information
- Founded
- MRNA 2010
- KOF 1979
- Country
- MRNA United States
- KOF Mexico
- Employees
- MRNA N/A
- KOF N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- KOF Beverages (Production/Distribution)
- Sector
- MRNA Health Care
- KOF Consumer Staples
- Exchange
- MRNA Nasdaq
- KOF Nasdaq
- Market Cap
- MRNA 16.0B
- KOF 16.3B
- IPO Year
- MRNA 2018
- KOF 1993
- Fundamental
- Price
- MRNA $35.53
- KOF $88.36
- Analyst Decision
- MRNA Hold
- KOF Strong Buy
- Analyst Count
- MRNA 20
- KOF 5
- Target Price
- MRNA $59.65
- KOF $104.75
- AVG Volume (30 Days)
- MRNA 13.6M
- KOF 202.7K
- Earning Date
- MRNA 02-14-2025
- KOF 02-21-2025
- Dividend Yield
- MRNA N/A
- KOF 3.65%
- EPS Growth
- MRNA N/A
- KOF 21.45
- EPS
- MRNA N/A
- KOF 5.42
- Revenue
- MRNA $3,236,000,000.00
- KOF $13,427,442,899.00
- Revenue This Year
- MRNA N/A
- KOF $13.12
- Revenue Next Year
- MRNA $21.39
- KOF $9.34
- P/E Ratio
- MRNA N/A
- KOF $16.31
- Revenue Growth
- MRNA N/A
- KOF 14.16
- 52 Week Low
- MRNA $29.25
- KOF $72.68
- 52 Week High
- MRNA $170.47
- KOF $102.28
- Technical
- Relative Strength Index (RSI)
- MRNA 48.60
- KOF 77.58
- Support Level
- MRNA $32.78
- KOF $83.30
- Resistance Level
- MRNA $36.98
- KOF $79.38
- Average True Range (ATR)
- MRNA 2.50
- KOF 2.19
- MACD
- MRNA 0.30
- KOF 0.92
- Stochastic Oscillator
- MRNA 66.81
- KOF 95.31
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About KOF Coca Cola Femsa S.A.B. de C.V.
Coca-Cola Femsa, a subsidiary of Femsa, is the largest franchise bottler of wide-moat Coca-Cola in volume terms. The company purchases beverage concentrates and syrup from Coca-Cola, which it then processes and packages for distribution through modern trade, traditional trade and the on-premises channel. Mexico and Brazil make up 80% of total sales, with the rest from other Central and South American countries, including Panama, Guatemala, Uruguay, and Argentina. Parent Femsa and Coca-Cola hold 47% and 28% of economic interests in Coca-Cola Femsa, through nonpublicly traded A and D shares, respectively, while controlling 56% and 33% of the respective voting power.